Sharon X. Wen

Array ( [id] => 12979876 [patent_doc_number] => 20170342163 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-30 [patent_title] => ANTI-HtrA1 ANTIBODIES AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 15/653201 [patent_app_country] => US [patent_app_date] => 2017-07-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30342 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15653201 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12118860 [patent_doc_number] => 20180002446 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-01-04 [patent_title] => 'ANTIBODIES TO MATRIX METALLOPROTEINASE 9' [patent_app_type] => utility [patent_app_number] => 15/644405 [patent_app_country] => US [patent_app_date] => 2017-07-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 38 [patent_figures_cnt] => 38 [patent_no_of_words] => 27804 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15644405 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12239950 [patent_doc_number] => 20180072813 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-15 [patent_title] => 'CARBONIC ANHYDRASE IX (G250) ANTIBODIES AND METHODS OF USE THEREOF' [patent_app_type] => utility [patent_app_number] => 15/590678 [patent_app_country] => US [patent_app_date] => 2017-05-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 37 [patent_figures_cnt] => 37 [patent_no_of_words] => 27986 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15590678 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16523814 [patent_doc_number] => 20200397894 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-24 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING CANCER [patent_app_type] => utility [patent_app_number] => 16/097021 [patent_app_country] => US [patent_app_date] => 2017-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44264 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16097021 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11836340 [patent_doc_number] => 20170218059 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-03 [patent_title] => 'Methods for Treating Thrombosis Using Chimeric and Humanized Anti-Histone Antibodies' [patent_app_type] => utility [patent_app_number] => 15/487747 [patent_app_country] => US [patent_app_date] => 2017-04-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 37007 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15487747 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18478314 [patent_doc_number] => 11692044 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-07-04 [patent_title] => Compositions and methods for the treatment of systemic inflammatory response syndromes [patent_app_type] => utility [patent_app_number] => 15/487619 [patent_app_country] => US [patent_app_date] => 2017-04-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 5 [patent_no_of_words] => 7329 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15487619 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14948437 [patent_doc_number] => 10435477 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-10-08 [patent_title] => Proprotein convertase subtilisin kexin type 9 binding proteins and uses thereof [patent_app_type] => utility [patent_app_number] => 16/091953 [patent_app_country] => US [patent_app_date] => 2017-04-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 3 [patent_no_of_words] => 7125 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 150 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16091953 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20200354 [patent_doc_number] => 12403119 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-02 [patent_title] => Treating lymphomas [patent_app_type] => utility [patent_app_number] => 15/452669 [patent_app_country] => US [patent_app_date] => 2017-03-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 3220 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 147 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15452669 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11743960 [patent_doc_number] => 20170198033 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-07-13 [patent_title] => 'SULFONATED SCLEROSTIN, ANTIBODIES, EPITOPES AND METHODS FOR IDENTIFICATION AND USE THEREFOR' [patent_app_type] => utility [patent_app_number] => 15/447496 [patent_app_country] => US [patent_app_date] => 2017-03-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 10254 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15447496 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11949514 [patent_doc_number] => 20170253666 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-07 [patent_title] => 'Methods for Treating Patients with Hyperlipidemia by Administering a PCSK9 Inhibitor in Combination with an ANGPTL3 Inhibitor' [patent_app_type] => utility [patent_app_number] => 15/446720 [patent_app_country] => US [patent_app_date] => 2017-03-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 14430 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15446720 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11969833 [patent_doc_number] => 20170273987 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-28 [patent_title] => 'Methods for Treating GI Syndrome and Graft versus Host Disease' [patent_app_type] => utility [patent_app_number] => 15/437165 [patent_app_country] => US [patent_app_date] => 2017-02-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 31 [patent_no_of_words] => 26807 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15437165 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12254231 [patent_doc_number] => 09926367 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-03-27 [patent_title] => 'Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof' [patent_app_type] => utility [patent_app_number] => 15/430100 [patent_app_country] => US [patent_app_date] => 2017-02-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 13411 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15430100 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11649489 [patent_doc_number] => 20170145391 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-25 [patent_title] => 'TRUNCATED VARIANT OF THE MAMMALIAN TARGET FOR RAPAMYCIN (mTOR) PROTEIN' [patent_app_type] => utility [patent_app_number] => 15/423377 [patent_app_country] => US [patent_app_date] => 2017-02-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 24402 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15423377 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12051252 [patent_doc_number] => 20170327595 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-16 [patent_title] => 'THERAPEUTIC AND DIAGNOSTIC METHODS RELATED TO LYSYL OXIDASE-LIKE 2 (LOXL2)' [patent_app_type] => utility [patent_app_number] => 15/416940 [patent_app_country] => US [patent_app_date] => 2017-01-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 43 [patent_figures_cnt] => 43 [patent_no_of_words] => 40069 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15416940 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11992480 [patent_doc_number] => 20170296635 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-19 [patent_title] => 'COMPOSITIONS AND METHODS COMPRISING GLYCYL-TRNA SYNTHETASES HAVING NON-CANONICAL BIOLOGICAL ACTIVITIES' [patent_app_type] => utility [patent_app_number] => 15/415328 [patent_app_country] => US [patent_app_date] => 2017-01-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 21 [patent_no_of_words] => 22413 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15415328 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15754077 [patent_doc_number] => 10619136 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-04-14 [patent_title] => Reducing immune tolerance induced by PD-L1 [patent_app_type] => utility [patent_app_number] => 15/373012 [patent_app_country] => US [patent_app_date] => 2016-12-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 13840 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 139 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15373012 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17890764 [patent_doc_number] => 11453717 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-09-27 [patent_title] => Trispecific antibodies against IL-17A, IL-17F and other pro-inflammatory molecule [patent_app_type] => utility [patent_app_number] => 16/097562 [patent_app_country] => US [patent_app_date] => 2016-12-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 29 [patent_no_of_words] => 27732 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16097562 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15280079 [patent_doc_number] => 10512689 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-12-24 [patent_title] => Compositions comprising a combination of nivolumab and ipilimumab [patent_app_type] => utility [patent_app_number] => 15/365717 [patent_app_country] => US [patent_app_date] => 2016-11-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 34 [patent_no_of_words] => 38239 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15365717 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16198638 [patent_doc_number] => 10723788 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-07-28 [patent_title] => Anti-complement factor C1q Fab fragments and uses thereof [patent_app_type] => utility [patent_app_number] => 15/360549 [patent_app_country] => US [patent_app_date] => 2016-11-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 24641 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15360549 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11491495 [patent_doc_number] => 20170065681 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-03-09 [patent_title] => 'USE OF CGRP ANTAGONIST COMPOUNDS FOR TREATMENT OF PSORIASIS' [patent_app_type] => utility [patent_app_number] => 15/355723 [patent_app_country] => US [patent_app_date] => 2016-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 13499 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15355723 [rel_patent_id] =>[rel_patent_doc_number] =>)